Search PubMed⌕ Search

Biomedical subjects

S D Bhandarkar

Publications and source records attributed to S D Bhandarkar.

At least 19 recordsLinked to original sources
PubMed1991

Antipyrine and doxycycline pharmacokinetics in patients with thyroid disorders.

Pathological conditions are known to affect pharmacokinetics of many drugs. Antipyrine half-life is used as a marker of liver microsomal enzyme function. Antipyrine pharmacokinetics, therefore, was investigated in 23 thyrotoxic and 11 euthyroid goitre patients. Of these, 11 thyrotoxic and 9 euthyroid goitre patients also participated in doxycycline bioavailability studies. In thyrotoxic patients, antipyrine half-life and AUCo infinity and doxycycline Cpmax and AUCo infinity were found to be reduced as compared to those of healthy euthyroid normal subjects. Following treatment of thyrotoxicosis, the antipyrine half-life and AUCo infinity returned to normal. Doxycycline AUCo infinity returned to near normal range but Cpmax did not.

Administration, Oral↗
PubMed1985

Chromosomal studies in diabetic patients treated with chlorpropamide.

Chromosome studies were carried out on the peripheral blood of nine diabetic patients treated with chlorpropamide, on nine healthy controls and on nine untreated diabetic controls. Data from each treated individual were compared with the mean of the pooled data from the two control groups. There was a statistically significant increase in the individual numbers of sister chromatid exchanges per metaphase in each of the patients treated with the drug compared with the mean of the pooled control values. There was no significant increase in the numbers of structural chromosomal aberrations in the treated patients compared with the controls.

Adult↗
PubMed1984

Drug interaction between chlorpropamide and non-steroidal anti-inflammatory drugs, ibuprofen and phenylbutazone.

Diabetics well controlled on chlorpropamide received, in randomized manner either 1200 mg of ibuprofen or 300 mg of phenylbutazone per day for rheumatic pains, for a period of 4 weeks. Fasting and postlunch, whole blood, true sugars (FBS and PLBS) were estimated at weekly intervals. Subjects taking phenylbutazone showed reduction in FBS values throughout the treatment; the reduction became statistically significant at the 3rd and 4th week. Clinical hypoglycemia, however, was not observed. The FBS values returned to pretreatment levels after stopping phenylbutazone. No significant reduction was seen in FBS in subjects taking ibuprofen. There was no significant change in PLBS values in either group.

Adult↗